Gentian Diagnostics ASA

Regulatory Filings • Aug 27, 2020

STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19

Moss, 27.08.20

Gentian Diagnostics AS is pleased to announce that the results from a study conducted in collaboration with Santa Lucia Hospital in Cartagena, Spain, are published in the scientific journal "Journal of Infection".

Results from the study confirm significantly elevated levels of calprotectin in patients with severe COVID-19 and indicate the role of calprotectin in assessment of disease severity and prediction of in-hospital mortality [1].

The study has investigated the role of two inflammation-associated biomarkers, calprotectin and growth differentiation factor-15 (GDF-15) in prediction of disease severity and mortality in 66 hospitalised patients with SARS-CoV-2 infection. Gentian Diagnostics' GCAL® (calprotectin) assay has been used in the study.

Several recent studies have reported increased levels of calprotectin in patients with severe SARS-Cov-2 infection, as well as the possibility of calprotectin to differentiate between mild and severe forms of the disease and ability to predict the need for mechanical ventilation and mortality [2-4].

References:

• 1. de Guadiana Romualdo L.G. et al. (2020) Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: a case series. Journal of Infection, doi.org/10.1016/j.jinf.2020.08.010
• 1. Shi H, et al. (2020) Neutrophil calprotectin identifies severe pulmonary disease in COVID-19, doi.org/10.1101/2020.05.06.20093070. Preprint PMID: 32511540
• 1. Zuo Y, et al.(2020) Neutrophil extracellular traps and thrombosis in COVID-19, doi.org/10.1101/2020.04.30.20086736. Preprint. PMID: 32511553
• 1. Silvin et al. (2020) Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 Cell, doi.org/10.1016/j.cell.2020.08.002